The Role of Biomarkers in Clinical Trials for Alzheimer Disease
Year: 2006
Type: article
Abstract: Biomarkers are likely to be important in the study of Alzheimer disease (AD) for a variety of reasons. A clinical diagnosis of Alzheimer disease is inaccurate even among experienced investigators in about 10% to 15% of cases, and biomarkers might improve the accuracy of diagnosis. Importantly for the development of putative disease-modifying drugs for Alzheimer disease, biomarkers might also serve as indirect measures of disease severity. When used in this way, sample sizes of clinical trials might be reduced, and a change in biomarker could be considered supporting evidence of disease modification. This review summarizes a meeting of the Alzheimer's Association's Research Roundtable, during which existing and emerging biomarkers for AD were evaluated. Imaging biomarkers including volumetric magnetic resonance imaging and positron emission tomography assessing either glucose utilization or ligands binding to amyloid plaque are discussed. Additionally, biochemical biomarkers in blood or cerebrospinal fluid are assessed. Currently appropriate uses of biomarkers in the study of Alzheimer disease, and areas where additional work is needed, are discussed.
Institutions: Sahlgrenska University Hospital, University of California San Diego, University of Gothenburg, Mayo Clinic, Translational Genomics Research Institute, University of Arizona, Banner - University Medical Center Phoenix, University of Pennsylvania, University of Pittsburgh Medical Center, University of Arkansas for Medical Sciences, United States Department of Veterans Affairs, Eli Lilly (United States), University of California, San Francisco, Veterans Health Administration, Elan Pharmaceuticals, Inc. (Ireland)
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1997526132
